Trial for Localised High-risk Rhabdomyosarcoma and Rhabdomyosarcoma-like Soft Tissue Sarcoma
A Randomised Phase-III Trial of the Cooperative Weichteilsarkom Study Group (CWS) for Localised High-risk Rhabdomyosarcoma and Localised Rhabdomyosarcoma-like Soft Tissue Sarcoma in Children, Adolescents, and Young Adults
Lead SponsorUniversity of Tuebingen
StatusCompleted No Results Posted
Indication/ConditionSoft Tissue Sarcoma
Intervention/Treatmentidarubicin cyclophosphamide etoposide ...
The purpose of this study is to investigate whether the addition of oral maintenance chemotherapy with O-TIE (Etoposide, Idarubicin, Trofosfamide) for 6 months improves the event free survival (EFS) in patients with localised high-risk RMS and RMS-like Soft Tissue Sarcoma.
oral maintenance therapy for 6 months
oral maintenance therapy with trofosfamide, idarubicin, and etoposide
Inclusion Criteria: written informed consent for registration, randomisation, data collection/transfer, and tumour material asservation available pathologically (including molecular pathology) proven diagnosis of rhabdomyosarcoma (RMS) or RMS-like soft tissue sarcoma (STS) and tumour material available for pathology review Rhabdomyosarcoma of the "High Risk" Group, i.e.: RME, N0, M0, IRS II&III, >5 cm or >10 years in EXT, HN-PM, OTH, UG-BP RME, N1, M0, any IRS-group, any size or age RMA, NO, M0, any IRS-group, any size or age (exception: paratesticular RMA are not eligible) or Rhabdomyosarcoma of the "Very High Risk" Group, i.e.: RMA, N1, MO, IRS II&III, any size or age or localised high-risk RMS-like Soft Tissue Sarcoma, i.e.: EES, pPNET, UDS: any N, M0, any IRS-group, any size or age SySa, any N, M0, any size or age (exception: SySa IRSI&II, not T2b, N0, M0 are not eligible) no pre-existing illness preventing treatment (esp. those listed in the medicinal product information, e.g. cardiac, hepatic, metabolic, or renal dysfunction; hypersensitivity) no previous malignant tumours available for long term follow up through the treating centre in remission (according to the CWS-2007-HR definition (see X7.1.8X)) at the time of randomisation after standard multimodal therapy e.g. according to the CWS-guidance Exclusion Criteria: pregnant or lactating women other medical condition precluding treatment with protocol therapy (e.g. HIV, psychiatric disorder, etc.) for sexually active females and males in Arm B (O-TIE treatment): refusal to use effective contraception (e.g. oral, IUD)